Thanks, Rick, for pointing attention to Thymitaq, GART, MMPI, and pre-clinical programs (VEGF, CMV, others). This is the next-good-news principle: you don't sell on the news when the next news is visible and on the way.
Some other companies have gotten to this point and their stock withered. For example, Cytogen's stock price started down on Prostacint approval, because there's nothing else in the tank. Gilead, same story -- other products are advancing, but are a ways off. Recently, GILD has rebounded as impending news has become more visible.
With four products in clinicals, AGPH should have a "next-news" event on the way for years! |
